Table 3 Relationship between pathological-complete response at breast and axilla with clinico-pathological factors
From: Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer
Variable N = 112 | pCR % (95% CI) | Univariate analysis p | Multivariate analysis HR (95% CI) p |
|---|---|---|---|
Age (years) | Â | 0.204 | Â |
   >50 | 64 (54–74) |  |  |
   <50 | 75 (67–83) |  |  |
Clinical T stage* | Â | 0.218 | Â |
   T2 | 54 (45–62) |  |  |
   T3 | 72 (64–80) |  |  |
   T4 | 75 (67–83) |  |  |
Clinical N stage* | Â | 0.072 | Â |
   N1 | 59(51–67) |  |  |
   N2/N3 | 78 (70–85) |  |  |
Clinical stage* | Â | 0.656 | Â |
   IIB | 66 (58–74) |  |  |
   IIIA | 66 (58–74) |  |  |
   IIIB | 75 (67–83) |  |  |
Estrogen receptors |  | 0.002 | 3.8 (0.149–0.087) 0.016 |
   Negative | 81 (74–88) |  |  |
   Positive | 54 (45–63) |  |  |
Progesterone receptors |  | 0.090 | 1.1 (0.391–3.571) 0.767 |
   Negative | 75 (67–83) |  |  |
   Positive | 60 (52–68) |  |  |
Histological grade†|  | 0.06 | 0.5 (0.244–1.038,) 0.063 |
   Low/moderate | 60 (52–68) |  |  |
   High | 76 (68–84) |  |  |